Another of the relevant biomarkers in NSCLC occurs in the receptor tyrosine kinase associated with MET and its ligand hepatocyte growth factor, leading to the activation of pathways such as AKT, ERK/MAPK or STAT 3. Here, MET is linked to non-small cell lung carcinoma.